- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter…
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year…
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose…
Figure 1 Combination of dulaglutide (Trulicity®) and buntanetap improves memory and synaptic plasticity in AD mice (*p<0.05, **p<0.01). Figure 2…
19,000-square-foot facility reflects the company’s recent growth and continued commitment to the regionMORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) --…
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial…
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025…
A$4.4 million of valid applications received for the Share Purchase PlanIn conjunction with recently completed A$8.0 million institutional placement, total…